Allarity Therapeutics Inc
NASDAQ:ALLR
Net Margin
Allarity Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Allarity Therapeutics Inc
NASDAQ:ALLR
|
13.6m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
324.6B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.5B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
132.2B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
117B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.4B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.8B USD |
-11%
|
Allarity Therapeutics Inc
Glance View
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-12-21. The firm is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The company uses its DRP companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by its DRP companion diagnostics platform. Its lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptor (VEGFR). Its second priority therapeutic candidate, stenoparib, is a selective inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). Its third priority therapeutic candidate is IXEMPRA (ixabepilone).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Allarity Therapeutics Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet